Finding, dating and proving public regulatory disclosures that can defeat a patent
Introduction
Food technology is a heavily regulated field. A company that develops a new sweetener, a plant-based protein, a processing method or an antimicrobial wash must usually engage with the Food and Drug Administration (FDA), the U.S. Department of Agriculture (USDA), or both, before the product reaches the market. These regulatory processes generate documents: notices, petitions, summaries, agency letters, dockets and public databases. Some of those documents are public and some become public on a predictable schedule.
For a party challenging a food technology patent, those documents can be a rich and often overlooked source of prior art. For a patent owner or an applicant, they are a reminder that regulatory strategy and patent strategy must be coordinated. This article explains how regulatory filings can qualify as prior art under U.S. law, which FDA and USDA submissions are most likely to be publicly accessible, how to find and authenticate them and how they are used in invalidity proceedings such as district court litigation, inter partes review and ex parte reexamination.
The Legal Framework for Prior Art
The America Invents Act categories
For patents governed by the America Invents Act (applications with an effective filing date on or after March 16, 2013), 35 U.S.C. 102(a)(1) treats an invention as unpatentable if, before the effective filing date, the claimed invention was patented, described in a printed publication, in public use, on sale, or otherwise available to the public. Section 102(a)(2) adds earlier-filed patent applications by others. Section 102(b) provides limited exceptions, including a one-year grace period for the inventor’s own disclosures and for disclosures by others who obtained the subject matter from the inventor. Older patents are governed by the pre-AIA statute, which has different categories and timing rules.
Printed publication: public accessibility
A document is a printed publication if it was publicly accessible, meaning that a person of ordinary skill interested in the subject matter, exercising reasonable diligence, could have located it. The Federal Circuit has addressed accessibility in many contexts, including In re Klopfenstein, 380 F.3d 1345 (Fed. Cir. 2004) and Blue Calypso, LLC v. Groupon, Inc., 815 F.3d 1331 (Fed. Cir. 2016). The inquiry turns on the facts: where the document was posted, how it was indexed, whether it was searchable, how long it remained available and who could access it. A document buried in an agency file and available only by special request is weaker than one posted in an indexed public docket or published in the Federal Register.
On-sale and public-use bars
Regulatory activity can also evidence commercial activity. Under Helsinn Healthcare S.A. v. Teva Pharmaceuticals USA, Inc., 139 S. Ct. 628 (2019), a commercial sale to a third party who is obliged to keep the invention confidential can still trigger the on-sale bar under the AIA. In food technology, that principle means that supply agreements, test-market sales, pilot shipments or commercial offers made while a regulatory submission is pending, even a confidential one, can start the clock or invalidate claims, regardless of whether the submission itself was public. The related test from Pfaff v. Wells Electronics, Inc., 525 U.S. 55 (1998), requires a commercial offer and readiness for patenting.
Enablement and the invention as claimed
To anticipate, a reference must disclose every element of the claim, arranged as claimed, in a way that enables a person of ordinary skill to make and use the invention. Printed publications are presumed enabling, as the Federal Circuit explained in In re Antor Media Corp., 689 F.3d 1282 (Fed. Cir. 2012), although the patentee may rebut the presumption. Regulatory documents often describe a product, its composition, manufacturing steps and intended uses in detail because agencies require that information to assess safety, which makes them strong candidates for anticipation or for obviousness combinations.
FDA Filings Most Likely to Be Prior Art
| Filing or record | What it contains | Public availability |
| GRAS notices (generally recognized as safe), 21 CFR Part 170, Subpart E | Identity of the substance, method of manufacture, specifications, intended use and levels and the basis for the safety conclusion | FDA posts notices and its response letters in a public inventory; confidential business information is redacted, so the posted version is the relevant prior art |
| Food additive petitions | Chemical identity, manufacturing, intended technical effect, safety data and proposed regulation | FDA publishes a notice of filing in the Federal Register and the petition and agency documents are generally available through the docket and FDA’s reading room, with trade secrets withheld |
| Color additive petitions | Composition, specification, manufacturing and safety data | Notice of filing published in the Federal Register; the resulting final rule is published and codified |
| Food contact substance notifications | Identity, intended use, technical effect, environmental information | FDA maintains public inventories of effective notifications; the underlying notification content is subject to confidentiality rules |
| New dietary ingredient notifications | Identity of the ingredient and evidence supporting safety under the conditions of use | FDA makes them available through public dockets, subject to redactions |
| Voluntary plant biotechnology consultations | Summaries of the developer’s safety and nutritional assessment of the new crop trait | FDA posts the consultation summaries and its closure letters |
| Citizen petitions, FDA rulemaking dockets, advisory committee materials | Technical arguments, data and scientific literature, often from competitors | Posted in public dockets (Regulations.gov); highly searchable |
| FOIA-released documents | Previously nonpublic submissions released after redaction | Public once released; date of release is key evidence of accessibility |
Two features of this regime are important for invalidity work. First, FDA withholds trade secrets and confidential commercial information under its regulations (see 21 CFR Part 20), so the question for a challenger is what the public version of the file disclosed and when. Second, the GRAS pathway has a voluntary notification component and a self-affirmed component: a company’s internal GRAS determination that is never submitted to FDA is not a public document and cannot be treated as a printed publication.
USDA Filings and Records
USDA’s regulatory role is split across several agencies, each with its own filings.
- Food Safety and Inspection Service (FSIS). FSIS regulates meat, poultry and certain egg products. Companies seeking approval of new processing technologies or antimicrobial interventions, or the use of novel ingredients, submit protocols and supporting data. The agency publishes lists of safe and suitable ingredients and related directives and some submissions or agency responses become public through guidance, notices and FOIA releases. Label applications for special statements and claims are reviewed by FSIS, but labels themselves are usually not published until they are in commerce, which is when they can become public-use or on-sale evidence.
- Animal and Plant Health Inspection Service (APHIS). Petitions for determination of non-regulated status of genetically engineered organisms, with the agency’s environmental and plant pest risk assessments, are published for public comment. These documents describe the genetic construct, the trait, its characterization and, often, the molecular methods used.
- Agricultural Marketing Service (AMS). For organic food and ingredients, petitions to add substances to the National List of Allowed and Prohibited Substances, together with technical reports and Advisory Board materials, are posted publicly and can describe in detail the process, composition and function of a new ingredient.
- Plant Variety Protection Office. Certificates and descriptions of protected plant varieties are public records and may be relevant to claims directed at crops, seeds and plant-derived food ingredients.
Strategies for Finding Regulatory Prior Art
- Define the claim’s core technical features. Break each claim into elements such as composition ranges, process steps, organisms, strains, intended uses and functional results, since regulatory documents describe these in agency-oriented language that may differ from patent claim language.
- Search the agency inventories and dockets. Use FDA’s GRAS notice inventory, food additive and color additive listings, the Federal Register, Regulations.gov dockets, USDA agency pages and the FOIA reading rooms. Search by substance name, CAS number, organism, process terms and intended technical effect, not just by the patent owner’s name.
- Search the patent owner’s competitors and predecessors. Regulatory filings from other companies, universities and trade associations may disclose the same technology independently and earlier.
- Check international counterparts. Filings with the European Food Safety Authority and other regulators, including published opinions and dossiers summaries, can reveal the same subject matter and may be printed publications in their own right.
- Use FOIA when necessary. If a promising filing is not public, a FOIA request may produce a redacted version. Plan for the delay and recognize that a document released after the critical date is not prior art unless it was accessible before then by other means.
- Look for related commercial activity. Press releases, trade-show materials, supply agreements, test batches and retailer announcements surrounding a regulatory submission may support on-sale or public-use theories.
Proving Date and Public Accessibility
Finding a document is half the work; the other half is establishing that it was prior art. The challenger bears the burden and the quality of the evidence often decides the outcome.
- Federal Register publications are self-authenticating public documents and their publication date is fixed.
- Agency websites and databases. Obtain archived versions (for example, from an internet archive) with a supporting declaration, capture posting dates, metadata and docket sequence numbers and document how the item was indexed and searchable.
- Docket records. Regulations.gov records typically display posting and receipt dates and comment periods that help to establish when the public could have viewed the file.
- Declarations and testimony. A declaration from an agency records custodian, a librarian or a person who accessed the document at the time can establish dissemination. Where available, certified agency copies simplify authentication under the rules of evidence.
- Evidence of skilled searchers. Showing that a skilled searcher exercising reasonable diligence could have located the document through ordinary subject-matter or keyword searches strengthens the accessibility case.
Practical point. A document is only as good as its date. A GRAS notice that was filed in one year but posted in the public inventory a year later is prior art as of the posting date, not the filing date, unless there is evidence that it was accessible earlier. Build the timeline from the public record.
Use in Different Proceedings
| Forum | What prior art is available | Notes for regulatory documents |
| District court | All categories of 102(a): printed publications, public use, sale and other public availability | Clear and convincing evidence standard for invalidity; regulatory filings can support anticipation, obviousness and on-sale arguments |
| Inter partes review (IPR) | Only patents and printed publications (35 U.S.C. 311(b)) | Regulatory documents must qualify as printed publications; confidential submissions and on-sale activity cannot be the basis for the grounds |
| Ex parte reexamination | Patents and printed publications | Lower cost route for a substantial new question of patentability based on a posted regulatory document |
| Post-grant review (PGR) | Broader grounds, including on-sale and public use, for AIA patents within nine months of grant | Useful where regulatory activity suggests early commercialization |
| ITC and other forums | Similar to district court | Evidence rules and timing differ; coordinate with counsel |
Anticipating Counterarguments
Patent owners respond to regulatory prior art in predictable ways and challengers should be ready for each.
- Not publicly accessible. The patentee argues the document was obscure, hard to find or posted later. The response is the date and accessibility evidence described above.
- Does not disclose every element. Regulatory summaries may omit details that the patent claims. A challenger can address this by combining references, relying on the knowledge of a skilled person for obviousness and, for anticipation, by showing inherent disclosure where the law permits.
- Not enabling. The patentee argues the filing does not teach how to make the product. The presumption of enablement for printed publications and the inclusion of manufacturing details required by regulators help to answer this.
- Redactions remove the key limitation. Where trade-secret redactions cover a claimed parameter, the reference may not disclose it. Evaluate what remains and whether other documents supply the missing information.
- The reference is the patentee’s own. The patentee may invoke the one-year grace period in section 102(b)(1) if the disclosure falls within that year. Dates matter and a third party’s subsequent disclosure must be examined for whether it derived from the inventor.
Implications for Applicants and Patent Owners
Regulatory and patent strategy should be planned together.
- File the patent application before the public regulatory step. Treat notices of filing, GRAS inventory postings, docket submissions and conference presentations as potential public disclosures and file before the first public event.
- Understand what will be public. Before submitting, decide with regulatory counsel what to designate as confidential, recognizing that redaction is an agency decision and some content will be public regardless.
- Control commercial activity. Avoid sales, offers, pilots or supply commitments before the application is filed, even under confidentiality.
- Audit the file. Before asserting a food technology patent, review the owner’s own regulatory submissions and those of competitors to identify risks and prepare to defend or narrow claims.
- Monitor the field. Competitor filings can indicate technology trends and help in clearing freedom to operate, as well as in building invalidity positions.
Conclusion
Regulatory submissions to the FDA and USDA are not merely compliance paperwork. When they are publicly accessible, they are printed publications that describe technology in detail and are dated by the agency’s own processes; when they are connected to sales or public use, they evidence commercial activity that can bar patenting. Challengers who search agency dockets, inventories and FOIA records systematically and who build a careful record of dates and accessibility, can find strong invalidity grounds that ordinary patent searches miss. Applicants and owners who understand the same pathways can avoid creating their own prior art and can build food technology patents that are more resilient.
This article is provided for general informational purposes only and does not constitute legal advice. Rules, fees and deadlines change; confirm current requirements with the relevant patent or trademark office and qualified counsel before acting.
